Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by ASTBURY, C.
Right arrow Articles by BIRD, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ASTBURY, C.
Right arrow Articles by BIRD, H. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 British Society for Rheumatology

other

METHYLSULPHASALAZINE IN RHEUMATOID ARTHRITIS

C. ASTBURY, J. HILL, J. R. LOWE, D. CAMPBELL* and H. A. BIRD

Clinical Pharmacology Unit (Rheumatism Research), Royal Bath Hospital Cornwall Road, Harrogate, North Yorkshire HG1 2PS, UKxs
*pharmacia AB Box 181, S-751 Uppsala 1, Sweden

Correspondence to: Correspondence to Dr H. Bird

Methylsulphasalazine, which differs from sulphasalazine by the addition of one methyl group, may provide the benefits of the parent drug with fewer side-effects in rheumatoid arthritis (RA). We describe the outcome of its use in RA. Of 21 patients entered into the study, 10 successfully completed 6 months of therapy; five developed adverse effects, four with drew for reasons unrelated to drug treatment and two stopped because of inefficacy. No serious adverse effects were reported. A statistically significant improvement in most clinical assessments was observed from weeks 8–12 onwards. Significant improvement in plasma viscosity was observed and there was a trend towards improvement in serum CRP, his tidine and IgM concentrations. There was a good correlation between mean serial changes in clinical and biochemical assessments indicating that the drug may exhibit the properties of a second-line agent. Median steady-state serum concen trations of methylsulphasalazine and methylsulphapyridine were 26.6 µg/ml and 2.85 µg/ml respectively.

KEY WORDS: Therapy, Sulphasalazine, Second-line agent


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.